Assessment of Acute Episodes in Chronic Stable Angina: A Clinical-Laboratory Approach to the Use of the Coronary Vasodilator Propatyl Nitrate

Background/Objectives: Propatyl nitrate is a coronary vasodilator with immediate and prolonged action, indicated in the treatment and prevention of acute angina pectoris episodes. Methods: This was an open, self-paired comparative study performed at UNIFESO Medical School evaluating the clinical and laboratory results of treatment with propatyl nitrate in patients with chronic stable angina pectoris. Subjects received 10 mg of propatyl nitrate, at the dose of three sublingual tablets per day, to be taken at 8:00 A.M., 2:00 P.M., and 8:00 P.M. Subjects returned to the study center after 15 days of treatment for Visit 2 assessments, and at the end of the 30-day treatment period (Visit 3). Results: A total of 200 subjects were included in the study. There was a statistically significant reduction in blood pressure (p < 0.0001) and heart rate (p = 0.0001), but no change in respiratory rate (p = 0.23). Laboratory results did not vary throughout the treatment period. There was no significant change from pretreatment in the SAQ Physical Limitation scale (p = 0.7415). The Angina Stability, Angina Frequency, and Treatment Satisfaction, and Quality of Life scales showed a significant improvement from pretreatment (p < 0.0001). Adverse events were observed among 41 subjects at Visit 2 and 35 subjects at Visit 3. Conclusions: Propatyl nitrate was safe and effective in treating chronic stable angina pectoris over the course of the 30-day treatment period. Treatment with propatyl nitrate increased angina stability and reduced angina frequency while increasing treatment satisfaction and quality of life in the patient population evaluated.

Soil Invertebrates in Different Land Use Systems： How Integrated Production Systems and Seasonality Affect Soil Mesofauna Communities

The soil mesofauna plays a role in organic matter comminution and decomposition, and can be used as bioindicators, since they are sensitive to soil management, vegetation and climate changes. Hence, this study aimed to evaluate mesofauna density and diversity in different land use systems to identify faunal relationships with soil properties, management and seasonality. The study area included five land use systems in Ponta Grossa municipality, Parana State： integrated crop-livestock （ICL）, integrated crop-livestock-forestry （ICLF）, grazed native pasture （NP）, Eucalyptus dunnii plantation （EU） and no-tillage （NT） cropping systems. In each system, eight soil samples for mesofauna were collected with Berlese funnels of 8 cm diameter along a transect in three replicate plots of 50 m × 100 m. For physical and chemical analysis, soil was sampled at five points per plot in two seasons： winter 2012 and autumn 2013. Data were statistically analyzed using ANOVA and Duncan＇s test （P 〈 0.05）, nonparametric statistics （when necessary） and redundancy analysis （RDA）. Diversity was calculated based on the group richness and Simpson index. The main mesofauna groups found were： Acarina, Collembola and Hymenoptera. Diplopoda, Enchytraeidae, Isopoda, Collembola, Hemiptera, Hymenoptera and Coleoptera larvae were more abundant in autumn than winter. Soil moisture was the main factor responsible for higher mesofauna abundance in autumn. Integrated production systems, especially ICLF had similar invertebrate community abundance and composition with EU, while NT favored Oribatid mites, although the use of insecticides, herbicides and fungicides reduced total mesofauna density. Most correlations between mesofauna and physical-chemical attributes in the winter were not observed in the autumn and vice versa, revealing that there are more factors involved in regulating soil mesofauna distribution.

Clinical Assessment of Treatment Outcomes Following Borago officinalis Extract Therapy in Patients Presenting with Cyclical Mastalgia

In order to evaluate the safety and efficacy of Borago officinalis (900 mg borage oil capsules) in the treatment of patients presenting with cyclic mastalgia, 91 subjects were included in the study. Efficacy assessments were performed based on data obtained prior to the start of treatment (Pretreatment), and after each menstrual cycle (Assessment 2—following 45 days of treatment;and Assessment 3—at the end of the 90-day treatment period). Primary efficacy measures considered the results of the Mastalgia Questionnaire, including a 100 mm visual analog pain scale assessing mean, most intense mastalgia severity, and impact on work, sleep, and sexual activity. Safety and tolerability measures included any changes in vital signs and physical exam in relation to pretreatment, any changes in clinical laboratory exams in relation to pretreatment, and the occurrence of adverse events after the first dose of study medication. The VAS scores of the mean mastalgia and most severe mastalgia both showed statistically significant